FR2797055B1 - Procede de criblage de molecules destinees au traitement de la maladie de huntington - Google Patents

Procede de criblage de molecules destinees au traitement de la maladie de huntington

Info

Publication number
FR2797055B1
FR2797055B1 FR9909855A FR9909855A FR2797055B1 FR 2797055 B1 FR2797055 B1 FR 2797055B1 FR 9909855 A FR9909855 A FR 9909855A FR 9909855 A FR9909855 A FR 9909855A FR 2797055 B1 FR2797055 B1 FR 2797055B1
Authority
FR
France
Prior art keywords
huntington
disease
treatment
screening molecules
screening
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9909855A
Other languages
English (en)
Other versions
FR2797055A1 (fr
Inventor
Christian Neri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fondation Jean Dausset-CEPH
Original Assignee
Fondation Jean Dausset-CEPH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fondation Jean Dausset-CEPH filed Critical Fondation Jean Dausset-CEPH
Priority to FR9909855A priority Critical patent/FR2797055B1/fr
Priority to EP00953231A priority patent/EP1200834A1/fr
Priority to PCT/FR2000/002036 priority patent/WO2001009613A1/fr
Priority to CA002380519A priority patent/CA2380519A1/fr
Publication of FR2797055A1 publication Critical patent/FR2797055A1/fr
Application granted granted Critical
Publication of FR2797055B1 publication Critical patent/FR2797055B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2835Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR9909855A 1999-07-29 1999-07-29 Procede de criblage de molecules destinees au traitement de la maladie de huntington Expired - Fee Related FR2797055B1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FR9909855A FR2797055B1 (fr) 1999-07-29 1999-07-29 Procede de criblage de molecules destinees au traitement de la maladie de huntington
EP00953231A EP1200834A1 (fr) 1999-07-29 2000-07-13 Procede de criblage de molecules destinees au traitement de la maladie de huntington
PCT/FR2000/002036 WO2001009613A1 (fr) 1999-07-29 2000-07-13 Procede de criblage de molecules destinees au traitement de la maladie de huntington
CA002380519A CA2380519A1 (fr) 1999-07-29 2000-07-13 Procede de criblage de molecules destinees au traitment de la maladie de huntington

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9909855A FR2797055B1 (fr) 1999-07-29 1999-07-29 Procede de criblage de molecules destinees au traitement de la maladie de huntington

Publications (2)

Publication Number Publication Date
FR2797055A1 FR2797055A1 (fr) 2001-02-02
FR2797055B1 true FR2797055B1 (fr) 2003-10-03

Family

ID=9548663

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9909855A Expired - Fee Related FR2797055B1 (fr) 1999-07-29 1999-07-29 Procede de criblage de molecules destinees au traitement de la maladie de huntington

Country Status (4)

Country Link
EP (1) EP1200834A1 (fr)
CA (1) CA2380519A1 (fr)
FR (1) FR2797055B1 (fr)
WO (1) WO2001009613A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4819101A (en) * 2000-04-13 2001-10-30 University Of British Columbia, The Modulating cell survival by modulating huntingtin function

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2116280A1 (fr) * 1993-03-05 1994-09-06 Marcy E. Macdonald Gene de la huntingtine, son produit et leurs utilisations
US6093549A (en) * 1995-11-09 2000-07-25 The Johns Hopkins University Huntingtin-associated protein-related assays
CA2238075A1 (fr) * 1995-11-17 1997-05-29 The University Of British Columbia Proteine ayant une interaction avec le gene de la maladie de huntington, adnc codant cette proteine et anticorps contre celle-ci

Also Published As

Publication number Publication date
FR2797055A1 (fr) 2001-02-02
EP1200834A1 (fr) 2002-05-02
WO2001009613A1 (fr) 2001-02-08
CA2380519A1 (fr) 2001-02-08

Similar Documents

Publication Publication Date Title
BR9600969A (pt) Método de tratamento de doença inflamatória cardíaca
FR2798592B1 (fr) Procede de traitement de troubles mataboliques, en particulier du diabete, ou d'une maladie ou d'une affection associee au diabete
CH1143977H1 (fr) 2-Oxy-benzoxazine-4-ones destinees au traitement de l'obesite
MA23941A1 (fr) Traitement des tissus
FR2794369B1 (fr) Traitement de la maladie de peyronie
MA25223A1 (fr) Procede pour la preparation de 4-carboxy-amino-2-substitue-1,2,3,4 tetrahydroquinoleine
KR970000230A (ko) 염증성 장 질환을 치료하기 위한 캅파-아편제 작용물질
EP1073368A4 (fr) Procede base sur l'aspiration permettant d'evaluer les risques de pneumonie encourus par un patient post-operatoire
MA26608A1 (fr) Procede de preparation d'une composition pharmaceutique destinee au traitement de l'insuffisance cardiaque.
FR2726994B1 (fr) Cage agrafe pour fracture de l'extremite superieure de l'humerus
NO20001869D0 (no) Fremgangsmõte for behandling av Alzheimerssykdom
FR2770216B1 (fr) Procede d'obtention de la forme polymorphe epsilon de l'hexanitrohexaazaisowurtzitane
BR9711225A (pt) Composi-{es de propentofilina transd-rmica para o tratamento do mal de alzheimer
FR2835255B1 (fr) Test pour identifier des inhibiteurs de beta-secretases, procede de criblage de ces inhibiteurs, et nouveaux inhibiteurs de beta-secretases pour leur utilisation dans le traitement de la maladie d'alzheimer
ITTO940748A0 (it) Condotto protesico particolarmente per il trattamento di patologie cardiovascolari.
NO20010953L (no) En fremgangsmåte for behandling av stafylokokkal sykdom
BR9610316A (pt) Composto processo para a produção e uso do mesmo processo para o tratamento de doença das vias aéreas e composição farmacêutica
FR2765591B1 (fr) Procede de diagnostic de la maladie d'alzheimer
FR2775919B1 (fr) Procede de traitement "mecano-chimique" d'un materiau
NO20012106L (no) Middel for behandling av forstyrrelser i benmetabolismen
FR2778574B1 (fr) Procede de mesure de l'effet d'un traitement sur un tissu
FR2797055B1 (fr) Procede de criblage de molecules destinees au traitement de la maladie de huntington
FR2733227B1 (fr) Procede pour la preparation de 1,1-difluoroethane
ATE230741T1 (de) 3-tetrahydropyridin-4-yl-indole zur behandlung von psychotischen störungen
FR2719240B1 (fr) Procédé de traitement des suspensions huileuses.

Legal Events

Date Code Title Description
ST Notification of lapse